 Shares of Jasper Therapeutics Inc. JSPR, 318.31 soared 283 in trading on Tuesday after the company said in a news release that its experimental therapy successfully helped three patients with sickle cell disease undergoing a bone marrow transplant. The Phase 12 clinical trial is assessing briquilimab as a way to help more patients improve donor chimerism, with less toxicity. 